Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
135 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergic Rhinitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H2 2017, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 8, 16, 4, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively. Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory). - The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Allergic Rhinitis - Overview 7 Allergic Rhinitis - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 18 Allergic Rhinitis - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Allergic Rhinitis - Companies Involved in Therapeutics Development 27 Accolade Pharmaceuticals LLC 27 AFFiRiS AG 27 ALK-Abello A/S 27 AlleCures Inc 28 Allergy Therapeutics Plc 29 ASIT Biotech SA 29 Axikin Pharmaceuticals Inc 30 Chong Kun Dang Pharmaceutical Corp 30 Chrysalis BioTherapeutics Inc 30 Fountain Biopharma Inc 31 GlaxoSmithKline Plc 31 Glenmark Pharmaceuticals Ltd 32 HAL Allergy BV 32 Hisamitsu Pharmaceutical Co Inc 33 Intrommune Therapeutics 33 J Uriach Y Compania SA 34 Laboratorios LETI SL 34 Paradigm Biopharmaceuticals Ltd 34 Sanofi 35 Stallergenes Greer plc 35 Sun Pharma Advanced Research Company Ltd 36 Taiho Pharmaceutical Co Ltd 36 Therabron Therapeutics Inc 37 Xencor Inc 37 Allergic Rhinitis - Drug Profiles 39 (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 39 (mometasone furoate + olopatadine hydrochloride) - Drug Profile 40 854-A - Drug Profile 41 Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile 42 Allergen for Allergic Rhinitis - Drug Profile 43 Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 44 Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 45 Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 46 Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 47 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 48 Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 49 Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 50 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 52 Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 53 arabinogalactan - Drug Profile 54 B-244 - Drug Profile 55 bepotastine besilate SR - Drug Profile 57 BM-41 - Drug Profile 58 CBP-174 - Drug Profile 59 CG-201 - Drug Profile 60 CPC-888 - Drug Profile 61 emedastine difumarate - Drug Profile 62 FB-825 - Drug Profile 63 gp-ASIT - Drug Profile 64 GSK-2245035 - Drug Profile 68 hdm-ASIT - Drug Profile 69 KR-62980 - Drug Profile 71 Lactococcus lactis G121 - Drug Profile 72 levocabastine hydrochloride + mometasone furoate - Drug Profile 73 mometasone furoate - Drug Profile 74 Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile 75 nasapaque - Drug Profile 76 NVP-1703 - Drug Profile 77 pentosan polysulfate sodium - Drug Profile 78 Pollinex Quattro Tree - Drug Profile 82 rag-ASIT - Drug Profile 84 rupatadine - Drug Profile 85 short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile 86 Small Molecule for Allergic Rhinitis - Drug Profile 87 Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 88 Small Molecules for Respiratory Disorders - Drug Profile 89 Small Molecules for Seasonal Allergic Rhinitis - Drug Profile 90 Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile 91 Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 92 standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 93 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 96 STG-120 - Drug Profile 101 SUN-0597 - Drug Profile 102 SYM-001 - Drug Profile 104 TAS-205 - Drug Profile 105 TO-206 - Drug Profile 106 Vaccine for Asthma and Allergic Rhinitis - Drug Profile 107 Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 108 XmAb-7195 - Drug Profile 109 Zafi-3 - Drug Profile 111 Allergic Rhinitis - Dormant Projects 112 Allergic Rhinitis - Discontinued Products 119 Allergic Rhinitis - Product Development Milestones 121 Featured News & Press Releases 121 Appendix 130 Methodology 130 Coverage 130 Secondary Research 130 Primary Research 130 Expert Panel Validation 130 Contact Us 130 Disclaimer 131
List of Tables
Number of Products under Development for Allergic Rhinitis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals LLC, H2 2017 Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2017 Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2017 Allergic Rhinitis - Pipeline by AlleCures Inc, H2 2017 Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2017 Allergic Rhinitis - Pipeline by ASIT Biotech SA, H2 2017 Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals Inc, H2 2017 Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017 Allergic Rhinitis - Pipeline by Fountain Biopharma Inc, H2 2017 Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2017 Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2017 Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017 Allergic Rhinitis - Pipeline by Intrommune Therapeutics, H2 2017 Allergic Rhinitis - Pipeline by J Uriach Y Compania SA, H2 2017 Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H2 2017 Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017 Allergic Rhinitis - Pipeline by Sanofi, H2 2017 Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2017 Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 Allergic Rhinitis - Pipeline by Therabron Therapeutics Inc, H2 2017 Allergic Rhinitis - Pipeline by Xencor Inc, H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..1), H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..2), H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..3), H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..4), H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..5), H2 2017 Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..6), H2 2017 Allergic Rhinitis - Discontinued Products, H2 2017 Allergic Rhinitis - Discontinued Products, H2 2017 (Contd..1), H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
